Spreadsheet: 116639d1311962231-designing-a-survey-in-excel-and-vb-questionnaire-on-nat-testing-of-blood-donations
Sheet: Definition-Results

Formularname | No.: | Year:
Questionnaire Draft | 1 | 2008
Preamble | Wert | Other | [NAME]
Questionnaire on NAT testing of blood donations | 0 | 0
0 | 0 | 0
0 | 0 | 0
Preamble | 0 | 0
0 | 0 | 0
This questionnaire has been designed and developed by the ISBT Working Party on Transfusion Transmitted Infectious Diseases. | 0 | 0
All rights reserved. The Working Party on Transfusion Transmitted Infectious Diseases (WP-TTID) is the constituent of the International | 0 | 0
Society of Blood Transfusion (ISBT) responsible  for evaluation and advocacy of ways to increase blood safety in the world in order to | 0 | 0
reduce the frequency of Transfusion Transmitted Infectious Diseases (TTID). | 0 | 0
0 | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0 |  |  |  | Definition - Results
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
#N/A | 0 | 0
Please complete this questionnaire and return it to: | 0 | 0
0 | 0 | 0
International Forums of Vox Sanguinis | 0 | 0
0 | 0 | 0
#N/A | 0 | 0
When information or data on specific terms is not available, please indicate “n.a.” (= data not yet available). | 0 | 0
#N/A | 0 | 0
Please return the completed questionnaire by: | 0 | 0
1. Close the questionnaire and save your changes | 0 | 0
2. Send an e-mail to: [EMAIL] and attach the file. | 0 | 0
#N/A | 0 | 0
Please note: | 0 | 0
#N/A | 0 | 0
Contact details | Wert | Other | [NAME]
Contact details | 0 | 0 | H1
0 | 0 | 0
0 | 0 | 0
Please fill in your personal data | 0 | 0 | H2
0 | 0 | 0
Country | 0 | 0 | C
0 | 0 | 0
Information provided by | 0 | 0
0 | 0 | 0
Family name | 0 | 0 | #2
0 | 0 | 0
First name | 0 | 0 | #2
0 | 0 | 0
Institution | 0 | 0 | #2
0 | 0 | 0
Address | 0 | 0 | #2
0 | 0 | 0
Phone | 0 | 0 | #2
0 | 0 | 0
Fax | 0 | 0 | #2
0 | 0 | 0
E-mail address | 0 | 0 | #2
0 | 0 | 0
0 | 0 | 0
Number of inhabitants in your country | 0 | 0 | #2
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
Time period
Time period | 0 | 0 | H1
Please select and provide data only for the selected year.testing |  | 0 | H2
Preferably, please provide data for |  | 0
2007 (complete) | 0 | 0 | #2
If data for 2007 are not yet completely available, please provide data for |  | 0
2006 (complete) | 0 | 0 | #2
If complete data for 2007 or 2006 are not available. |  | 0 | H3
Please specify period for provided data: | 0 | 0 | #3O
If changes in test procedures/test systems have been made during the indicated year. same assay |  | 0 | H3
Please specify: | 0 | 0 | #3O
1. HIV
HIV screening |  | 0 | H1
HIV screening |  | 0
anti-HIV 1+2 | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HIV p24 Ag | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HIV Combo test (antibody + antigen) | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
2. HIV
HIV screening |  | 0
HIV rapid test | 0 | 0 | #1H2
only pre-donation screening | 0 | 0 | #2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HIV NAT | 0 | 0 | #1H2
mandated by government | 0 | 0 | #2
performed since | 0 | 0 | #2O
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
HIV-1 subtype N covered by the assay | 0 | 0 | #2
HIV-1 subtype O covered by the assay | 0 | 0 | #2
HIV-2 covered by the assay | 0 | 0 | #2
3. HIV
HIV screening | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 |  | 0
HIV NAT is performed using: | 0 | 0 | H3
Commercial assay | 0 | 0 | #3
please specify supplier | 0 | 0 | #3
please specify test used | 0 | 0 | #3
In house assay please indicate : | 0 | 0 | #3
technology used  (e.g. PCR, real-time PCR, TMA etc.) | 0 | 0 | #3
sensitivity |  | 0
95% detection limit in IU/ml with respect to 1 ml of individual donor plasma) | 0 | 0 | #3
50% detection limit in IU/ml with respect to 1 ml of individual donor plasma) | 0 | 0 | #3
specificity (%) | 0 | 0 | #3
HIV subtypes covered by the assay | 0 | 0 | #3
0 | 0 | 0
HIV NAT is performed as | 0 | 0 | H3
individual donation NAT (ID NAT) | 0 | 0 | #3
mini pool NAT | 0 | 0 | #3O
4. HIV
HIV screening | 0 | 0
0 | 0 | 0
Run controls used for HIV NAT | 0 | 0 | H3
part of commercial assay | 0 | 0 | #3
other commercial supplier, please specify | 0 | 0 | #3O
WHO standard | 0 | 0 | #3
National standard, please specify | 0 | 0 | #3O
In house standard, please specify | 0 | 0 | #3O
0 | 0 | 0
Availability of run controls | 0 | 0 | H3
sufficient | 0 | 0 | #3
not sufficient, please specify | 0 | 0 | #3O
0 | 0 | 0
If HIV NAT is not performed, please indicate reasons | 0 | 0 | #2
Is the introduction of HIV NAT planned? | 0 | 0 | #2
5. HIV
HIV test results | 0 | 0 | H1
0 | 0 | 0
Number of donations tested serologically during the indicated year | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Number of donations tested by NAT during the indicated year | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Number of invalid NAT test results during the indicated year (%) | 0 | 0 | #1H2
6. HIV
Confirmed seropositive* | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Proportion of NAT positives among confirmed seropositives**** | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
7. HIV
HIV test results | 0 | 0
0 | 0 | 0
NAT only positives***** | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Total number of donations tested by NAT since its introduction† | 0 | 0 | #1H2
0 | 0 | 0
NAT only positives***** since introduction of NAT testing† | 0 | 0 | H2
Donations from first time tested donors**, number† | 0 | 0 | #2
Donations from repeat tested donors***, number† | 0 | 0 | #2
8. HIV
HIV test results | 0 | 0
0 | 0 | 0
Number of HIV NAT initial reactives during the indicated year | 0 | 0 | #1H2
Proportion of not confirmed positives, number | 0 | 0 | #1H2
0 | 0 | 0
Confirmation of HIV NAT initial reactives | 0 | 0 | H2
repeat testing by same assay | 0 | 0 | #2
supplementary NAT test (e.g. different amplicon, increased sensitivity, ID NAT) | 0 | 0 | #2
serological testing (antigen/antibody) | 0 | 0 | #2
second blood sample | 0 | 0 | #2
0 | 0 | 0
Did you calculate the residual transmission risk? If yes, please indicate your result and specify the algorithm. | 0 | 0 | #1H2
9. HIV
HIV test results | 0 | 0
0 | 0 | 0
Please indicate HIV-1 subtypes prevalent in your country: | 0 | 0 | H2
A, percentage (if data available) | 0 | 0 | #2O
B, percentage (if data available) | 0 | 0 | #2O
C, percentage (if data available) | 0 | 0 | #2O
D, percentage (if data available) | 0 | 0 | #2O
E, percentage (if data available) | 0 | 0 | #2O
F, percentage (if data available) | 0 | 0 | #2O
G, percentage (if data available) | 0 | 0 | #2O
H, percentage (if data available) | 0 | 0 | #2O
J, percentage (if data available) | 0 | 0 | #2O
K, percentage (if data available) | 0 | 0 | #2O
CRF (circulating recombinant forms), please specify and indicate percentage | 0 | 0 | #2O
O, percentage (if data available) | 0 | 0 | #2O
N, percentage (if data available) | 0 | 0 | #2O
0 | 0 | 0
Please indicate HIV-2 prevalence in your country | 0 | 0 | #2
10. HIV
HIV test results | 0 | 0
0 | 0 | 0
Please indicate HIV-1 subtypes prevalent in your donor population: | 0 | 0 | H2
A, percentage (if data available) | 0 | 0 | #2O
B, percentage (if data available) | 0 | 0 | #2O
C, percentage (if data available) | 0 | 0 | #2O
D, percentage (if data available) | 0 | 0 | #2O
E, percentage (if data available) | 0 | 0 | #2O
F, percentage (if data available) | 0 | 0 | #2O
G, percentage (if data available) | 0 | 0 | #2O
H, percentage (if data available) | 0 | 0 | #2O
J, percentage (if data available) | 0 | 0 | #2O
K, percentage (if data available) | 0 | 0 | #2O
CRF (circulating recombinant forms), please specify and indicate percentage | 0 | 0 | #2O
O, percentage (if data available) | 0 | 0 | #2O
N, percentage (if data available) | 0 | 0 | #2O
0 | 0 | 0
Please indicate HIV-2 prevalence in your donor population | 0 | 0 | #2
1. HCV
HCV screening |  | 0 | H1
HCV screening |  | 0
anti-HCV | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HCV core Ag | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HCV Combo test (antibody + antigen) | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
2. HCV
HCV screening |  | 0
HCV rapid test | 0 | 0 | #1H2
only pre-donation screening | 0 | 0 | #2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HCV NAT | 0 | 0 | #1H2
mandated by government | 0 | 0 | #2
performed since | 0 | 0 | #2O
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
3. HCV
HCV screening | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 |  | 0
HCV NAT is performed using: | 0 | 0 | H3
Commercial assay | 0 | 0 | #3
please specify supplier | 0 | 0 | #3
please specify test used | 0 | 0 | #3
In house assay please indicate : | 0 | 0 | #3
technology used  (e.g. PCR, real-time PCR, TMA etc.) | 0 | 0 | #3
sensitivity |  | 0
95% detection limit in IU/ml with respect to 1 ml of individual donor plasma) | 0 | 0 | #3
50% detection limit in IU/ml with respect to 1 ml of individual donor plasma) | 0 | 0 | #3
specificity (%) | 0 | 0 | #3
HCV genotypes covered by the assay | 0 | 0 | #3
0 | 0 | 0
HCV NAT is performed as | 0 | 0 | H3
individual donation NAT (ID NAT) | 0 | 0 | #3
mini pool NAT | 0 | 0 | #3O
4. HCV
HCV screening | 0 | 0
0 | 0 | 0
Run controls for used for HCV NAT | 0 | 0 | H3
part of commercial assay | 0 | 0 | #3
other commercial supplier, please specify | 0 | 0 | #3O
WHO standard | 0 | 0 | #3
National standard, please specify | 0 | 0 | #3O
In house standard, please specify | 0 | 0 | #3O
0 | 0 | 0
Availability of run controls | 0 | 0 | H3
sufficient | 0 | 0 | #3
not sufficient, please specify | 0 | 0 | #3O
0 | 0 | 0
If HCV NAT is not performed, please indicate reasons | 0 | 0 | #2
Is the introduction of HCV NAT planned? | 0 | 0 | #2
5. HCV
HCV test results | 0 | 0 | H1
0 | 0 | 0
Number of donations tested serologically during the indicated year | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Number of donations tested by NAT during the indicated year | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Number of invalid NAT test results during the indicated year (%) | 0 | 0 | #1H2
6. HCV
Confirmed seropositive* | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Proportion of NAT positives among confirmed seropositives**** | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
7. HCV
HCV test results | 0 | 0
0 | 0 | 0
NAT only positives***** | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Total number of donations tested by NAT since its introduction† | 0 | 0 | #1H2
0 | 0 | 0
NAT only positives***** since introduction of NAT testing† | 0 | 0 | H2
Donations from first time tested donors**, number† | 0 | 0 | #2
Donations from repeat tested donors***, number† | 0 | 0 | #2
8. HCV
HCV test results | 0 | 0
0 | 0 | 0
Number of HCV NAT initial reactives | 0 | 0 | #1H2
Proportion of not confirmed positives, number | 0 | 0 | #1H2
0 | 0 | 0
Confirmation of HCV NAT initial reactives | 0 | 0 | H2
repeat testing by same assay | 0 | 0 | #2
supplementary NAT test (e.g. different amplicon, increased sensitivity, ID NAT) | 0 | 0 | #2
serological testing (antigen/antibody) | 0 | 0 | #2
second blood sample | 0 | 0 | #2
0 | 0 | 0
Would you consider using HCV core antigen testing instead of HCV NAT in the future? Please indicate your reasons: | 0 | 0 | #1H2
0 | 0 | 0
Did you calculate the residual transmission risk? If yes, please indicate your result and specify the algorithm. | 0 | 0 | #1H2
9. HCV
HCV test results | 0 | 0
0 | 0 | 0
Please indicate HIV-1 subtypes prevalent in your country: | 0 | 0 | H2
1a, percentage (if data available) | 0 | 0 | #2O
1b, percentage (if data available) | 0 | 0 | #2O
2, percentage (if data available) | 0 | 0 | #2O
3, percentage (if data available) | 0 | 0 | #2O
4, percentage (if data available) | 0 | 0 | #2O
5, percentage (if data available) | 0 | 0 | #2O
6, percentage (if data available) | 0 | 0 | #2O
0 | 0 | 0
Please indicate HCV genotypes prevalent in your donor population: | 0 | 0 | H2
1a, percentage (if data available) | 0 | 0 | #2O
1b, percentage (if data available) | 0 | 0 | #2O
2, percentage (if data available) | 0 | 0 | #2O
3, percentage (if data available) | 0 | 0 | #2O
4, percentage (if data available) | 0 | 0 | #2O
5, percentage (if data available) | 0 | 0 | #2
6, percentage (if data available) | 0 | 0 | #2O
1. HBV
HBV screening |  | 0 | H1
HBV screening |  | 0
HBsAg | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
anti-HBc | 0 | 0 | #1H2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
2. HBV
HBV screening |  | 0
HBV rapid test | 0 | 0 | #1H2
only pre-donation screening | 0 | 0 | #2
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
please specify supplier | 0 | 0 | #2
please specify test used | 0 | 0 | #2
HBV NAT | 0 | 0 | #1H2
mandated by government | 0 | 0 | #2
performed since | 0 | 0 | #2O
only 1st time donor | 0 | 0 | #2
every donation | 0 | 0 | #2
3. HBV
HBV screening | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 |  | 0
HBV NAT is performed using: | 0 | 0 | H3
Commercial assay | 0 | 0 | #3
please specify supplier | 0 | 0 | #3
please specify test used | 0 | 0 | #3
In house assay please indicate : | 0 | 0 | #3
technology used  (e.g. PCR, real-time PCR, TMA etc.) | 0 | 0 | #3
sensitivity |  | 0
95% detection limit in IU/ml with respect to 1 ml of individual donor plasma) | 0 | 0 | #3
50% detection limit in IU/ml with respect to 1 ml of individual donor plasma) | 0 | 0 | #3
specificity (%) | 0 | 0 | #3
HBV genotypes covered by the assay | 0 | 0 | #3
0 | 0 | 0
HBV NAT is performed as | 0 | 0 | H3
individual donation NAT (ID NAT) | 0 | 0 | #3
mini pool NAT | 0 | 0 | #3O
4. HBV
HBV screening | 0 | 0
0 | 0 | 0
Run controls for used for HBV NAT | 0 | 0 | H3
part of commercial assay | 0 | 0 | #3
other commercial supplier, please specify | 0 | 0 | #3O
WHO standard | 0 | 0 | #3
National standard, please specify | 0 | 0 | #3O
In house standard, please specify | 0 | 0 | #3O
0 | 0 | 0
Availability of run controls | 0 | 0 | H3
sufficient | 0 | 0 | #3
not sufficient, please specify | 0 | 0 | #3O
0 | 0 | 0
If HBV NAT is not performed, please indicate reasons | 0 | 0 | #2
Is the introduction of HBV NAT planned? | 0 | 0 | #2
0 | 0 | 0
Are HBV vaccination programs effective in your country? | 0 | 0 | #1H2
since when? | 0 | 0 | #2O
vaccination only of persons at risk | 0 | 0 | #2
general vaccination program | 0 | 0 | #2
age of persons at the time of vaccination | 0 | 0 | #2O
percentage of vaccinated persons | 0 | 0 | #2O
5. HBV
HBV test results | 0 | 0 | H1
0 | 0 | 0
Number of donations tested serologically during the indicated year | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Number of donations tested by NAT during the indicated year | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Number of invalid NAT test results during the indicated year (%) | 0 | 0 | #1H2
6. HBV
Confirmed HBsAg positive* | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
HBsAg and anti-HBc and NAT positive | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
HBsAg and NAT positive, anti-HBc negative | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
7. HBV
HBV test results | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
Confirmed anti-HBc positive, NAT negative and HBsAg negative**** | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
Confirmed anti-HBc positive and NAT positive, HBsAg negative | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
NAT only positive (HBsAg and anti-HBc negative)***** | 0 | 0 | H2
Donations from first time tested donors**, number | 0 | 0 | #2
Donations from repeat tested donors***, number | 0 | 0 | #2
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
8.HBV
Total number of donations tested by NAT since its introduction† | 0 | 0 | #1H2
0 | 0 | 0
0 | 0 | 0 | H2
NAT only positives***** since introduction of NAT testing† | 0 | 0 | #2
Donations from first time tested donors**, number† | 0 | 0 | #2
Donations from repeat tested donors***, number† | 0 | 0
0 | 0 | 0
0 | 0 | 0
Total number of NAT and anti-HBc positive, HBsAg negative test results since introduction of NAT testing† | 0 | 0 | H2
Donations from first time tested donors**, number† | 0 | 0 | #2
Donations from repeat tested donors***, number† | 0 | 0 | #2
0 | 0 | 0
0 | 0 | 0
0 | 0 | 0
Total number of NAT and HBsAg positive, anti-HBc negative test results since introduction of NAT testing† | 0 | 0 | H2
Donations from first time tested donors**, number† | 0 | 0 | #2
Donations from repeat tested donors***, number† | 0 | 0 | #2
9. HBV
HBV test results | 0 | 0
0 | 0 | 0
Number of HBV NAT initial reactives | 0 | 0 | #1H2
Proportion of not confirmed positives, number | 0 | 0 | #1H2
0 | 0 | 0
Confirmation of HBV NAT only reactives | 0 | 0 | H2
repeat testing by same assay | 0 | 0 | #2
supplementary NAT test (e.g. different amplicon, increased sensitivity, ID NAT) | 0 | 0 | #2
serological testing (antigen/antibody) | 0 | 0 | #2
second blood sample | 0 | 0 | #2
0 | 0 | 0
Did you calculate the residual transmission risk? If yes, please indicate your result and specify the algorithm. | 0 | 0 | #1H2
10. HBV
HBV test results | 0 | 0
0 | 0 | 0
Please indicate HBV genotypes prevalent in your country: | 0 | 0 | H2
A, percentage (if data available) | 0 | 0 | #2O
B, percentage (if data available) | 0 | 0 | #2O
C, percentage (if data available) | 0 | 0 | #2O
D, percentage (if data available) | 0 | 0 | #2O
E, percentage (if data available) | 0 | 0 | #2O
F, percentage (if data available) | 0 | 0 | #2O
G, percentage (if data available) | 0 | 0 | #2O
H, percentage (if data available) | 0 | 0 | #2O
Please indicate HBV genotypes prevalent in your donor population: | 0 | 0 | H2
A, percentage (if data available) | 0 | 0 | #2O
B, percentage (if data available) | 0 | 0 | #2O
C, percentage (if data available) | 0 | 0 | #2O
D, percentage (if data available) | 0 | 0 | #2O
E, percentage (if data available) | 0 | 0 | #2O
F, percentage (if data available) | 0 | 0 | #2O
G, percentage (if data available) | 0 | 0 | #2O
H, percentage (if data available) | 0 | 0 | #2O
1. Others
Screening for other viral agents | 0 | 0 | H1
0 | 0 | 0
Whole blood donations | 0 | 0 | H2
0 | 0 | 0
HTLV I/II | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
West Nile Virus | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
Parvovirus B19 | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
HAV | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
Apheresis donations | 0 | 0 | H2
0 | 0 | 0
HTLV I/II | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
West Nile Virus | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
Parvovirus B19 | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
HAV | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
2. Others
Screening for other viral agents | 0 | 0
0 | 0 | 0
Whole blood donations | 0 | 0 | H2
0 | 0 | 0
HEV | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
[NAME] | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
Dengue Virus | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
other, please specify | 0 | 0 | H3O
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
Apheresis donations | 0 | 0 | H2
0 | 0 | 0
HEV | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
[NAME] | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
Dengue Virus | 0 | 0 | #2H3
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
0 | 0 | 0
other, please specify | 0 | 0 | H3O
serology | 0 | 0 | #3
NAT | 0 | 0 | #3
 |  |  | END